Fig. 6: CoVEXS5 protects against SARS-CoV-1 infection. | npj Vaccines

Fig. 6: CoVEXS5 protects against SARS-CoV-1 infection.

From: An adjuvanted chimeric spike antigen boosts lung-resident memory T-cells and induces pan-sarbecovirus protective immunity

Fig. 6: CoVEXS5 protects against SARS-CoV-1 infection.

Hamsters were vaccinated with CoVEXS5 (5 or 20 μg) or mRNA-XBB (5 μg) as shown in (A), and infected with SARS-CoV-1 Tor-2 variant at 21 days post-final vaccination. Change in body weight after challenge (B), viral loads in nasal turbinates or lung at Day 3 post challenge (C) and neutralisation titres to SARS-CoV-1 live virus (D) is also shown. Significant differences between group were determined by two-way (B) or one-way (C) ANOVA with Tukey’s multiple comparison test; *p < 0.05, **p < 0.01, ****p < 0.0001. A created with Biorender.

Back to article page